Cash conversion cycle: pharmaceutical industry analysis

Cash conversion cycle analysis in the pharmaceutical industry adds inventory days and receivable days, then subtracts payable days. Calculate it from finance exports with the same product-line and period scope, and separate inventory by stage before interpreting the total. A shorter cycle needs an explanation in actual stock, collection, and supplier-payment movements.

Fix the scope before opening the workbook

Use a manufacturing business or product line with recognized inventory, credit sales, trade receivables, and operating trade payables. Keep distributor sell-in revenue separate from downstream patient demand. The general cash conversion cycle guide owns the full definition and underlying formula.

Cash conversion cycle = Inventory days + Receivable days - Payable days

Inventory days = Average inventory / Period cost of goods sold × Period days

Receivable days = Average trade receivables / Period net credit sales × Period days

Payable days, COGS proxy = Average operating trade payables / Period cost of goods sold × Period days

The CFA Institute's financial analysis reading identifies inventory, receivable, and payable days as activity measures and the cash conversion cycle as a liquidity measure. These balance-to-flow calculations are estimates, not a traced elapsed time for a particular batch.

Collect the exports and declare the basis

Bring opening and closing inventory balances by product line, inventory stage, and lot. Add the period's net credit-sales and cost of goods sold totals, trade-receivable balances by distributor, and operating-payable balances by supplier. Retain adjustment and posting dates.

This illustrative US manufacturer uses a 90-day period. All revenue is net credit sales, all balances are USD, and receivables and sales follow the same adjustment basis. Average balances use opening plus closing divided by two; use more frequent snapshots when quarter-end balances are unrepresentative.

Calculate inventory days by stage

Put this table on an Inventory sheet, with stage in A, opening balance in B, closing balance in C, average balance in D, and days contribution in E. Rows 2 through 5 contain the stages; row 6 contains totals.

Enter these formulas and copy D2:E2 through row 5:

D2 =(B2+C2)/2
E2 =D2/Inputs!$B$4*Inputs!$B$2
B6 =SUM(B2:B5)
C6 =SUM(C2:C5)
D6 =SUM(D2:D5)
E6 =SUM(E2:E5)

The check is =D6/Inputs!B4*Inputs!B2: it must equal E6. Thus 6,000,000 / 3,600,000 × 90 = 150.0 days. Stage contributions share the same total COGS denominator; 20.0 quarantine days does not mean lots spend that long awaiting release.

Keep categories mutually exclusive. The published US warehousing rule specifies quarantine before quality-control release and appropriate storage conditions. Treat release status as an operational constraint. Quality owns release status, production owns work in process, procurement reviews raw materials, and planning reviews released stock; finance reconciles their balances to inventory accounts.

Finish receivable days, payable days, and the cycle

Use these formulas for the remaining components:

DSO =((Inputs!B5+Inputs!B6)/2)/Inputs!B3*Inputs!B2
DPO =((Inputs!B7+Inputs!B8)/2)/Inputs!B4*Inputs!B2
CCC =Inventory!E6+DSO-DPO

Here DSO and DPO denote named result cells. Alternatively, substitute their cell references in the CCC formula.

Average receivables are (3,300,000 + 4,700,000) / 2 = $4,000,000; average payables are (1,300,000 + 1,900,000) / 2 = $1,600,000. Display days to one decimal place after calculating.

COGS includes costs that need not match supplier purchases. This payable-days proxy is not average invoice-payment time. Review invoice dates, due dates, payment dates, and purchases separately before attributing a change to supplier terms.

Compare product lines and test an improvement

Repeat the calculation for each product line and period using its own matched balances, sales, and costs. Document allocations for shared supplier balances. Rebuild the company result from summed balances and flows, rather than averaging product-line cycles. For external comparisons, use cash conversion cycle by industry to keep business scope visible.

Suppose average inventory falls by $200,000 through lower purchasing against unchanged sales and COGS:

Daily COGS is 3,600,000 / 90 = $40,000; five days at that rate corresponds to $200,000 of inventory investment. Confirm the cash effect in purchasing and payment records: a write-down can reduce balances without releasing cash.

Where pharmaceutical cash-cycle analysis goes wrong

• Double-counted quarantine. Quarantined finished goods must not also remain in the released-stock category.
• Distributor scope changes. Acquisitions, customer transfers, and sell-in versus downstream measures can change the comparison population.
• Mismatched rebates and deductions. Reconcile credit memos and adjustments across receivables and sales before interpreting collection days.
• Different product-line allocations. Moving shared payables between lines changes their cycles without changing company cash timing.
• Write-offs presented as cash. Separate valuation changes, physical reductions, and actual collections or payments.

Compare your own pharmaceutical exports in Covirage

Bring inventory-stage balances, distributor receivables, supplier payables, and matching sales and cost exports; Covirage maps the columns, and its tools compute and check the component days and totals. The external AI model explains the results with every figure traced to its rows. Create a free Covirage account and bring a sample of your own data.

See Covirage for pharmaceutical teams for the supporting industry context.